205 related articles for article (PubMed ID: 16970400)
21. Anaplastic lymphoma kinase (ALK)-induced malignancies: novel mechanisms of cell transformation and potential therapeutic approaches.
Wasik MA; Zhang Q; Marzec M; Kasprzycka M; Wang HY; Liu X
Semin Oncol; 2009 Apr; 36(2 Suppl 1):S27-35. PubMed ID: 19393833
[TBL] [Abstract][Full Text] [Related]
22. Molecular variant of the NPM-ALK rearrangement of Ki-1 lymphoma involving a cryptic ALK splice site.
Ladanyi M; Cavalchire G
Genes Chromosomes Cancer; 1996 Mar; 15(3):173-7. PubMed ID: 8721682
[TBL] [Abstract][Full Text] [Related]
23. Inhibitors of the RET tyrosine kinase based on a 2-(alkylsulfanyl)-4-(3-thienyl)nicotinonitrile scaffold.
Brandt W; Mologni L; Preu L; Lemcke T; Gambacorti-Passerini C; Kunick C
Eur J Med Chem; 2010 Jul; 45(7):2919-27. PubMed ID: 20409618
[TBL] [Abstract][Full Text] [Related]
24. Crystal structures of IRAK-4 kinase in complex with inhibitors: a serine/threonine kinase with tyrosine as a gatekeeper.
Wang Z; Liu J; Sudom A; Ayres M; Li S; Wesche H; Powers JP; Walker NP
Structure; 2006 Dec; 14(12):1835-44. PubMed ID: 17161373
[TBL] [Abstract][Full Text] [Related]
25. Synthesis and structure-activity relationships of 1,2,3,4-tetrahydropyrido[2,3-b]pyrazines as potent and selective inhibitors of the anaplastic lymphoma kinase.
Milkiewicz KL; Weinberg LR; Albom MS; Angeles TS; Cheng M; Ghose AK; Roemmele RC; Theroff JP; Underiner TL; Zificsak CA; Dorsey BD
Bioorg Med Chem; 2010 Jun; 18(12):4351-62. PubMed ID: 20483621
[TBL] [Abstract][Full Text] [Related]
26. Identification of NPM-ALK interacting proteins by tandem mass spectrometry.
Crockett DK; Lin Z; Elenitoba-Johnson KS; Lim MS
Oncogene; 2004 Apr; 23(15):2617-29. PubMed ID: 14968112
[TBL] [Abstract][Full Text] [Related]
27. Role of signal transducer and activator of transcription 5 in nucleophosmin/ anaplastic lymphoma kinase-mediated malignant transformation of lymphoid cells.
Nieborowska-Skorska M; Slupianek A; Xue L; Zhang Q; Raghunath PN; Hoser G; Wasik MA; Morris SW; Skorski T
Cancer Res; 2001 Sep; 61(17):6517-23. PubMed ID: 11522649
[TBL] [Abstract][Full Text] [Related]
28. Discovery and structure-activity relationship of 3-aminopyrid-2-ones as potent and selective interleukin-2 inducible T-cell kinase (Itk) inhibitors.
Charrier JD; Miller A; Kay DP; Brenchley G; Twin HC; Collier PN; Ramaya S; Keily SB; Durrant SJ; Knegtel RM; Tanner AJ; Brown K; Curnock AP; Jimenez JM
J Med Chem; 2011 Apr; 54(7):2341-50. PubMed ID: 21391610
[TBL] [Abstract][Full Text] [Related]
29. Structure-based design of a potent, selective, and irreversible inhibitor of the catalytic domain of the erbB receptor subfamily of protein tyrosine kinases.
Singh J; Dobrusin EM; Fry DW; Haske T; Whitty A; McNamara DJ
J Med Chem; 1997 Mar; 40(7):1130-5. PubMed ID: 9089334
[TBL] [Abstract][Full Text] [Related]
30. Fold recognition, homology modeling, docking simulations, kinetics analysis and mutagenesis of ATP/CTP:tRNA nucleotidyltransferase from Methanococcus jannaschii.
Bujnicki JM; Albert MA; Nelson DJ; Thurlow DL
Proteins; 2003 Aug; 52(3):349-59. PubMed ID: 12866049
[TBL] [Abstract][Full Text] [Related]
31. Determination of the structure of human phosphodiesterase-2 in a bound state and its binding with inhibitors by molecular modeling, docking, and dynamics simulation.
Hamza A; Zhan CG
J Phys Chem B; 2009 Mar; 113(9):2896-908. PubMed ID: 19708117
[TBL] [Abstract][Full Text] [Related]
32. Characterization of a conserved structural determinant controlling protein kinase sensitivity to selective inhibitors.
Blencke S; Zech B; Engkvist O; Greff Z; Orfi L; Horváth Z; Kéri G; Ullrich A; Daub H
Chem Biol; 2004 May; 11(5):691-701. PubMed ID: 15157880
[TBL] [Abstract][Full Text] [Related]
33. Structural biology contributions to tyrosine kinase drug discovery.
Cowan-Jacob SW; Möbitz H; Fabbro D
Curr Opin Cell Biol; 2009 Apr; 21(2):280-7. PubMed ID: 19208462
[TBL] [Abstract][Full Text] [Related]
34. Identification of novel inhibitors of tropomyosin-related kinase A through the structure-based virtual screening with homology-modeled protein structure.
Park H; Chi O; Kim J; Hong S
J Chem Inf Model; 2011 Nov; 51(11):2986-93. PubMed ID: 22017333
[TBL] [Abstract][Full Text] [Related]
35. The design, synthesis and biological evaluation of 7-alkoxy-4-heteroarylamino-3-cyanoquinolines as dual inhibitors of c-Src and iNOS.
Cao X; You QD; Li ZY; Liu XR; Xu D; Guo QL; Shang J; Chern JW; Chen ML
Bioorg Med Chem Lett; 2008 Dec; 18(23):6206-9. PubMed ID: 18930653
[TBL] [Abstract][Full Text] [Related]
36. IKKbeta inhibitors identification part I: homology model assisted structure based virtual screening.
Nagarajan S; Doddareddy Mr; Choo H; Cho YS; Oh KS; Lee BH; Pae AN
Bioorg Med Chem; 2009 Apr; 17(7):2759-66. PubMed ID: 19285872
[TBL] [Abstract][Full Text] [Related]
37. Design and synthesis of 5-aryl-pyridone-carboxamides as inhibitors of anaplastic lymphoma kinase.
Li R; Xue L; Zhu T; Jiang Q; Cui X; Yan Z; McGee D; Wang J; Gantla VR; Pickens JC; McGrath D; Chucholowski A; Morris SW; Webb TR
J Med Chem; 2006 Feb; 49(3):1006-15. PubMed ID: 16451066
[TBL] [Abstract][Full Text] [Related]
38. EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors.
Choi YL; Soda M; Yamashita Y; Ueno T; Takashima J; Nakajima T; Yatabe Y; Takeuchi K; Hamada T; Haruta H; Ishikawa Y; Kimura H; Mitsudomi T; Tanio Y; Mano H;
N Engl J Med; 2010 Oct; 363(18):1734-9. PubMed ID: 20979473
[TBL] [Abstract][Full Text] [Related]
39. Abl inhibitor BMS354825 binding mode in Abelson kinase revealed by molecular docking studies.
Gambacorti-Passerini C; Gasser M; Ahmed S; Assouline S; Scapozza L
Leukemia; 2005 Jul; 19(7):1267-9. PubMed ID: 15858616
[No Abstract] [Full Text] [Related]
40. Pyrazolone-based anaplastic lymphoma kinase (ALK) inhibitors: control of selectivity by a benzyloxy group.
Tripathy R; McHugh RJ; Ghose AK; Ott GR; Angeles TS; Albom MS; Huang Z; Aimone LD; Cheng M; Dorsey BD
Bioorg Med Chem Lett; 2011 Dec; 21(24):7261-4. PubMed ID: 22061645
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
